MICAFUNGIN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for micafungin sodium and what is the scope of freedom to operate?
Micafungin sodium
is the generic ingredient in four branded drugs marketed by Apotex, Biocon Pharma, Fresenius Kabi Usa, Hikma, Jiangsu Hansoh Pharm, Meitheal, Xellia Pharms Aps, Zydus Pharms, Astellas, Endo Operations, Teva Pharms Usa Inc, and Baxter Hlthcare Corp, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.There are eight drug master file entries for micafungin sodium. Thirteen suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for MICAFUNGIN SODIUM
US Patents: | 0 |
Tradenames: | 4 |
Applicants: | 12 |
NDAs: | 12 |
Drug Master File Entries: | 8 |
Finished Product Suppliers / Packagers: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 39 |
Clinical Trials: | 5 |
Patent Applications: | 121 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MICAFUNGIN SODIUM |
What excipients (inactive ingredients) are in MICAFUNGIN SODIUM? | MICAFUNGIN SODIUM excipients list |
DailyMed Link: | MICAFUNGIN SODIUM at DailyMed |
Recent Clinical Trials for MICAFUNGIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shandong Provincial Hospital | Phase 4 |
Astellas Pharma China, Inc. | |
Seoul National University Hospital | Phase 2 |
Generic filers with tentative approvals for MICAFUNGIN SODIUM
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | EQ 100MG BASE/VIAL | INJECTABLE;INTRAVENOUS |
⤷ Sign Up | ⤷ Sign Up | EQ 50MG BASE/VIAL | INJECTABLE;INTRAVENOUS |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for MICAFUNGIN SODIUM
Drug Class | Echinocandin Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for MICAFUNGIN SODIUM
Paragraph IV (Patent) Challenges for MICAFUNGIN SODIUM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MYCAMINE | For Injection | micafungin sodium | 50 mg/vial 100 mg/vial | 021506 | 1 | 2014-06-16 |
US Patents and Regulatory Information for MICAFUNGIN SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | MICAFUNGIN IN SODIUM CHLORIDE 0.9% | micafungin sodium | SOLUTION;INTRAVENOUS | 216142-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Pharms Usa Inc | MICAFUNGIN | micafungin sodium | POWDER;INTRAVENOUS | 212125-002 | Jul 30, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 208366-002 | Nov 5, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Biocon Pharma | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 216438-001 | May 29, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MICAFUNGIN SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-003 | Jun 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-003 | Jun 27, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.